Cargando…
Characterization of a monoclonal antibody to L1210 leukaemia.
A mouse of monoclonal cell line (L1) was produced by fusing the mouse myeloma P3X63/Ag8 with CD2F1 spleen cells immunized with a highly immunogenic subline of L1210 leukaemia (L1210/DTIC). A very few positive clones (1%) were isolated and one of these was chosen for detailed study. The monoclonal an...
Autores principales: | Testorelli, C., Morelli, S., Goldin, A., Nicolin, A. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1982
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2010931/ https://www.ncbi.nlm.nih.gov/pubmed/7073934 |
Ejemplares similares
-
Serotherapy of L1210 murine leukaemia--reasons for ineffectiveness of in vivo treatment by L.1 monoclonal antibody.
por: Testorelli, C., et al.
Publicado: (1983) -
Development of cyclosporin A mediated immunity in L1210 leukaemia.
por: Slater, L. M., et al.
Publicado: (1991) -
Adriamycin/cyclophosphamide and adriamycin/melphalan in advanced L1210 leukaemia.
por: Tobias, J. S., et al.
Publicado: (1975) -
Effect of VM-26 on the haematological responses of mice to L1210 leukaemia.
por: Hacker, M., et al.
Publicado: (1980) -
Influence of micrococcus, BCG and related polysaccharides on the proliferation of the L1210 leukaemia.
por: Verloes, R., et al.
Publicado: (1978)